BUZZ-丹纳赫第二季度业绩超预期后上涨

Reuters07-23

((自动化翻译由路透提供，请见免责声明 ))

7月23日 - ** 生命科学公司丹纳赫股价盘前大涨7.8%至270.54美元

** 公司公布的第二季度每股收益为1.72美元，高于分析师平均预期的1.57美元。

** 第二季度营收为 57.4 亿美元，也高于分析师预计的 55.9 亿美元。

**DHR 表示，其用于开发生物疗法的产品和服务出现了 "持续的积极势头

** 其测试业务 Cepheid 在本季度扩大了市场份额

** 公司认为 2024 年核心收入将出现低个位数下降

** 截至上次收盘，股价累计上涨 8.5

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2453080117?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-23 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453080117","market":"us","top_or_hot":-1,"title":"BUZZ-丹纳赫第二季度业绩超预期后上涨","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    7月23日 - ** 生命科学公司<a href=\"https://laohu8.com/S/DHR\">丹纳赫</a>  股价盘前大涨7.8%至270.54美元</p><p>** 公司公布的第二季度每股收益为1.72美元，高于分析师平均 预期的1.57美元。</p><p>** 第二季度营收为 57.4 亿美元，也 高于分析师预计的 55.9 亿美元。 </p><p>**DHR 表示， 其用于开发生物疗法的产品和服务出现了 \"持续的积极势头</p><p>     ** 其测试业务 Cepheid 在本季度扩大了市场份额</p><p>** 公司认为 2024 年核心收入将出现低个位数下降</p><p>** 截至上次收盘，股价累计上涨 8.5 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-丹纳赫第二季度业绩超预期后上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-丹纳赫第二季度业绩超预期后上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-23 19:16 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    7月23日 - ** 生命科学公司丹纳赫  股价盘前大涨7.8%至270.54美元** 公司公布的第二季度每股收益为1.72美元，高于分析师平均 预期的1.57美元。** 第二季度营收为 57.4 亿美元，也 高于分析师预计的 55.9 亿美元。 **DHR 表示， 其用于开发生物疗法的产品和服务出现了 \"持续的积极势头     ** 其测试业务...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2453080117","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453080117","pubTimestamp":1721733381,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    7月23日 - ** 生命科学公司丹纳赫  股价盘前大涨7.8%至270.54美元** 公司公布的第二季度每股收益为1.72美元，高于分析师平均 预期的1.57美元。** 第二季度营收为 57.4 亿美元，也 高于分析师预计的 55.9 亿美元。 **DHR 表示， 其用于开发生物疗法的产品和服务出现了 \"持续的积极势头     ** 其测试业务 Cepheid 在本季度扩大了市场份额** 公司认为 2024 年核心收入将出现低个位数下降** 截至上次收盘，股价累计上涨 8.5","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4504":"桥水持仓","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2063271972.USD":"富兰克林创新领域基金","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4534":"瑞士信贷持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4121":"生命科学工具和服务","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","BK4588":"碎股","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","DHR":"丹纳赫","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","BUZZ":"VanEck Social Sentiment ETF","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"BUZZ-Danaher Rises After Beating Q2 Results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"DHR":1},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    7月23日 - ** 生命科学公司丹纳赫  股价盘前大涨7.8%至270.54美元** 公司公布的第二季度每股收益为1.72美元，高于分析师平均 预期的1.57美元。** 第二季度营收为 57.4 亿美元，也 高于分析师预计的 55.9 亿美元。 **DHR 表示， 其用于开发生物疗法的产品和服务出现了 \"持续的积极势头     ** 其测试业务 Cepheid 在本季度扩大了市场份额** 公司认为 2024 年核心收入将出现低个位数下降** 截至上次收盘，股价累计上涨 8.5","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453080117"}